Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Evaluate the Efficacy and Safety of AMG 102 and Avastin in Subjects With Recurrent Malignant Glioma

NCT01113398 is registered in ClinicalTrials.gov with Katy Peters as lead sponsor.

NCT NCT01113398
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01113398 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Evaluate the Efficacy and Safety of AMG 102 and Avastin in Subjects With Recurrent Malignant Glioma
Lead sponsor
Katy Peters
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2010
Completion date
September 30, 2015
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme, gliosarcoma